Dietary supplements for aggressive behaviour in people with intellectual disabilities: A randomised controlled crossover trial. Issue 1 (12th October 2022)

• Record Type: Journal Article
• Authors: Gast, David A. A.; Didden, Robert; Westera, Johanna J.; van de Rest, Ondine; van Hemert, Albert M.; Giltay, Erik J.
• Is Part Of: Journal of applied research in intellectual disabilities. Volume 36:Issue 1(2023)
• Page Start: 122
• Page End: 131
• Publication Date: 2022-10-12
• Subjects: aggressive behaviour -- dietary supplements -- intellectual disabilities -- randomised controlled trial; Learning disabilities -- Periodicals; Mental retardation -- Periodicals; Learning disabled -- Periodicals; People with mental disabilities -- Periodicals; 616.85880072
• DOI: 10.1111/jar.13041
• Languages: English
• ISSNs: 1360-2322

Abstract

Abstract: Background: Aggressive incidents are common in people with intellectual disabilities. Therefore, we aimed to assess whether supplementation of multivitamins, minerals, and omega‐3 fatty acids (FA) reduces aggressive incidents. Methods: We conducted a randomised, triple blind, placebo controlled, single crossover intervention trial. People with intellectual disabilities or borderline intellectual functioning, between 12 and 40 years of age, and showing aggressive behaviour were included. Participants received either a daily dose of dietary supplements, or placebo. Primary outcome was the number of aggressive incidents, measured using the Modified Overt Aggression Scale (MOAS). Results: there were 113 participants (placebo, n = 56), of whom 24 (placebo, n = 10) participated in the crossover phase of the trial. All 137 trajectories were included in the analyses. There was no significant difference in mean number of aggressive incidents per day between those assigned to supplements and those who received placebo (rate ratio = 0.93: 95% Confidence Interval [CI] = 0.59–1.45). Conclusion: In this pragmatic trial, we did not find significant differences in the outcomes between the supplement and placebo arms. The COVID‐19 pandemic started midway through our trial, this may have affected the results.